RSS Feed ALL

Johnson & Johnson Unveils Global Insights on the Future of Surgical Software

about 1 hour ago

Survey of nearly 700 clinicians across more than 600 surgical facilities in...

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

about 1 hour ago

New Drug Application supported by results from the Phase 2b SunRISe-1 study

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

1 day ago

Johnson & Johnson reports Q2 2025 results; raises 2025 outlook

1 day ago

2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational...

Johnson & Johnson Marks 25 Years of Neurovascular Care with New Innovation Highlights at SNIS 2025

3 days ago

Accepted abstracts include discussion of novel embolization approach to treating migraine and...

Johnson & Johnson Receives FDA Approval for Updated VARIPULSE™ Platform Irrigation Rate

3 days ago

New flow rate guidance designed to optimize irrigation and support consistent procedural...

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

9 days ago

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction...

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer an

14 days ago

The submission is based on results from the Phase 3 AMPLITUDE study...

Johnson & Johnson Launches thePolyphonicTM AI Fund for Surgery to Advance Data-Driven Healthcare

22 days ago

Open call for innovation to help accelerate promising artificial intelligence (AI) solutions...

Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens1 - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM

24 days ago

World’s leading* contact lens brand ACUVUE brings pioneering innovation for astigmatic patients...

IMAAVYTM (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

24 days ago

The ITC compared all published Phase 3 data of these treatments, leveraging...

DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma

27 days ago

If approved, daratumumab will be the first authorised treatment option for patients...